Catalyst Pharmaceuticals, Inc.
CPRX
$21.12
-$0.21-0.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -0.28% | 10.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.28% | 10.20% | |||
| Cost of Revenue | -14.32% | 12.77% | |||
| Gross Profit | 2.79% | 9.65% | |||
| SG&A Expenses | 6.15% | -3.68% | |||
| Depreciation & Amortization | 0.01% | -0.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.17% | 1.53% | |||
| Operating Income | 0.83% | 23.44% | |||
| Income Before Tax | -3.90% | 29.68% | |||
| Income Tax Expenses | -20.26% | 36.96% | |||
| Earnings from Continuing Operations | 1.43% | 27.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.43% | 27.46% | |||
| EBIT | 0.83% | 23.44% | |||
| EBITDA | 0.73% | 19.78% | |||
| EPS Basic | 0.11% | 26.45% | |||
| Normalized Basic EPS | 0.43% | 20.69% | |||
| EPS Diluted | 2.67% | 25.23% | |||
| Normalized Diluted EPS | 1.20% | 20.85% | |||
| Average Basic Shares Outstanding | 1.32% | 0.81% | |||
| Average Diluted Shares Outstanding | 0.54% | 0.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||